lesterol precursor lathosterol were higher in carriers of the CH25H 4 haplotype. In 1,282 patients with AD and 1,312 healthy control subjects from fi ve independent populations, a common variation in the vicinity of CH25H was signifi cantly associated with the risk for sporadic AD (p = 0.006). Quantitative neuropathology of brains from elderly non-demented subjects showed brain A ␤ deposits in carriers of CH25H 4 and CH25H 3 haplotypes, whereas no A ␤ deposits were present in CH25H 2 carriers. Together, these results are compatible with a role of CH25H 4 as a putative susceptibility factor for sporadic AD; they may explain part of the linkage of chromosome 10 markers with sporadic AD, and they suggest the possibility that CH25H polymorphisms are associated with different rates of brain A ␤ deposition. neurofi brillary tangles and the degeneration of specifically vulnerable brain neurons. We observed high expression of the cholesterol 25-hydroxylase (CH25H) gene in specifi cally vulnerable brain regions of AD patients. CH25H maps to a region within 10q23 that has been previously linked to sporadic AD. Sequencing of the 5 region of CH25H revealed three common haplotypes, CH25H 2 , CH25H 3 and CH25H 4 ; CSF levels of the cho-
Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by ␤ -amyloid ( ␤ A) plaques, neurofi brillary tangles (NFTs) and the degeneration of specifi cally vulnerable brain neurons. Degeneration of neurons in AD occurs predominantly in such brain regions as the hippocampus, the inferior temporal cortex, the entorhinal cortex and the amygdala. The relative protection from degeneration of neuronal populations in the frontal and the occipital cortex [1] indicates selective vulnerability of specifi c neurons in brain regions involved in cognitive and memory processes. We previously demonstrated specifi c downregulation of seladin-1 (DHCR24) , encoding 24-dehydrocholesterol reductase (seladin-1), in the inferior temporal cortex in AD using a differential mRNA display approach [2] ; downregulation of DHCR24 is reportedly associated with pathologic phosphorylation of tau, the major proteinaceous constituent of NFTs in AD [3] .
In this study, we targeted a priori CH25H , encoding cholesterol 25-hydroxylase. The intronless CH25H codes for a polytopic membrane protein of 272 amino acids and plays an important role in lipid metabolism [4] . By synthesizing 25-hydroxycholesterol, a potent co-repressor of SREBP (sterol regulatory element binding protein) processing, CH25H is involved in the transcriptional regulation of lipid-related genes. Importantly, CH25H maps within a 30-cM-broad region on chromosome 10q, which has been recently linked to late-onset AD [5] [6] [7] . In addition, CH25H is known to be upregulated in the spinal cord of patients with amyotrophic lateral sclerosis [8] , suggesting a potential role in neurodegeneration.
Because recent genetic evidence suggests that cholesterol-and lipid-related genes are associated with the risk for AD [9] [10] [11] [12] [13] [14] , we examined the differential expression of CH25H in AD, its potential association with disease risk, as well as its association with A ␤ plaque deposition.
Subjects and Methods

Differential mRNA Expression Studies
Brain tissues from 12 aged individuals with Braak stages ranging from 0 to 6 were dissected and immediately frozen in liquid nitrogen, on average within 5 h postmortem. Brain areas for differential expression analysis were identifi ed and stored at -80 ° C until RNA extractions were performed. In order to compare RNA populations from carefully selected postmortem brain tissues (hippocampus, and frontal and inferior temporal cortex), qPCR using the LightCycler TM was employed. The ratio of the normalized amount of candidate gene cDNA from the temporal cortex or hippocampus and frontal cortex was determined (relative quantifi cation). The following strategy was used for normalization: Xenopus ␤ -globin mRNA spiked into the mRNA of each brain tissue was used as a qPCR standard to normalize differences in the cDNA synthesis effi ciency. Additionally, the qPCR procedure was applied to a set of housekeeping genes, which were selected as a reference standard for quantifi cation. The ratio of the amount of frontal and temporal mRNA of fi ve such housekeeping genes (cyclophilin B, ribosomal protein S9, ␤ -actin, GAPDH and transferrin receptor) was determined, the mean value from the fi ve ratios calculated and used for normalization of candidate gene expression. Primers for qPCR of CH25H were 5 -GGT CAA CAT CTG GCT TTC CG-3 (forward) and 5 -CAC CAG TCT GTG AGT GGA CCA A-3 (reverse).
Genetic Association Studies
Genetic studies were conducted on fi ve independent populations: a Swiss sample (174 AD patients and 285 controls), a Mediterranean sample from Greece and Italy (272 AD patients and 125 controls), a Russian sample (74 AD patients and 90 controls), a French sample (551 AD patients and 665 controls) and a US sample derived from the NIMH Human Genetics Initiative and from the National Cell Repository for Alzheimer's Disease (NCRAD; grant No. U24 AG21886; 211 AD patients and 147 controls). The diagnosis of AD was performed according to the NINCDS-ADRDA criteria. The control groups comprised cognitively healthy elderly individuals who were either the spouses of AD patients or subjects recruited from the outpatient clinics of the participating institutions.
Neuropathological Studies
Neuropathological examinations were performed in the brains of 71 elderly individuals (mean age of death: 71.6 years, range 50-91 years, 28 females) devoid of signifi cant neuropathological abnormalities and without signs of dementia, as measured by the Clinical Dementia Rating scale [15] . The evolutionary phases (0-4) of ␤ -amyloidosis in the medial temporal lobe of these subjects were determined as described previously [16, 17] . NFT staging (0-6) was performed according to Braak and Braak [18] . For genotype determination, DNA was extracted from fresh-frozen samples of cerebelli following standard protocols.
CSF Studies
CSF was obtained by lumbar puncture in a subset of the participants of the genetic studies in Zurich. Forty-fi ve AD patients (mean age: 70.1 years) and 27 healthy elderly subjects (mean age: 65.4 years) were included. For CSF A ␤ 42 analysis, we used a sandwich ELISA (INNOTEST ␤ -Amyloid 1-42, Innogenetics) with mAb 21F12 -specifi c for the free C-terminal end of A ␤ 42 (peptide sequence A ␤ 33-42) -as capturing antibody and mAb 3D6 -specifi c for the N-terminal end of A ␤ 42 (peptide sequence A ␤ 1-5) -as detector. CSF lathosterol was measured by means of combined gas chromatography/mass spectrometry [19] .
SNP Selection and Genotyping
Information on polymorphic sites of 10q23-24 was derived from the database of single nucleotide polymorphisms (dbSNP) established by the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/SNP/index.html), and from the Celera database (www.celera.com). The following genes were se-lected due to possible relevance for AD: PTEN (phosphatase and tensin homolog), ACTA2 ( ␣ 2 -actin), TNFRSF6 (tumor necrosis factor receptor superfamily, member 6), CH25H (cholesterol 25-hydroxylase), LIPA (lipase A), PPP1R3C (protein phosphatase 1, regulatory subunit 3C), CYP2C8 [cytochrome P 450 , subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8], TLL2 (tolloid-like 2), SLIT1 (slit homolog 1), PGAM1 (phosphoglycerate mutase 1), SFRP5 (secreted frizzled-related protein 5), HPA2 (heparanase 2), GOT1 (glutamic-oxaloacetic transaminase 1), COX15 (COX15 homolog), WNT8B (wingless-type MMTV integration site family), NEURL (neuralized-like), SLK (Ste20-related serine/threonine kinase), and GSTTLp28 (glutathione-S-transferase like). In these genes, the following SNPs were analyzed: rs1903858, rs1389, rs1324551, hCV399212, rs13500, rs1131706, rs1556478, rs1051339, rs1051338, rs1044563, rs2068888, rs1058932, rs730179, rs902471, rs716838, rs1126878, rs2075430, rs1556971, rs2236278, rs2970, rs1047425, rs805657, and rs4925. SNP identifi cation in the ORF, the 5 and the 3 region of CH25H , was done by double-stranded sequencing of 40 chromosomes on an ABI PRISM ® 310 Genetic Analyzer. The Masscode TM system was used for SNP genotyping [20] .
Statistics
Genotype and allelic frequencies between AD patients and controls were compared by Fisher's exact tests. Forward and backward unconditional logistic regression analyses were done for the simultaneous assessment of the infl uence of age, gender, APOE and CH25H genotypes on the risk for developing AD. The estimate haplotype frequencies program was used to test for linkage disequilibrium (LD) between SNPs and for signifi cance of haplotype distribution between AD cases and controls [21] . The FBAT and SDT algorithms were used for family-based association analysis [22] .
Phases of ␤ -amyloidosis between groups were compared with the U test by Wilcoxon, and Mann and Whitney. The signifi cance of correlation between CH25H mRNA expression levels and NFT stages was assessed by Spearman's rank correlation coeffi cient. For the comparison of CSF A ␤ 42 and lathosterol levels, t tests were used.
Results
First-Stage Analysis
Using comprehensive differential display [23, 24] and real-time quantitative PCR analyses, we observed high CH25H (encoding cholesterol 25-hydroxylase) expression in such vulnerable brain regions as the inferior temporal cortex and the hippocampus in AD patients ( fi g. 1 ).
We then sequenced the ORF and 6.8 kb of the 5 genomic region of CH25H and identifi ed two synonymous SNPs, four 3 SNPs, and six 5 SNPs. Haplotype analysis revealed three common haplotypes, designated CH25H 2 , CH25H 3 and CH25H 4 , composed of SNP CH25H*1 at -6443 bp and SNP CH25H*2 at -6627 bp ( fi g. 2 ). 
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Distance from CH25H ✽ 1 (kb) Genetic data in Caucasian populations ( www.celera. com ) indicate that both CH25H*1 and CH25H*2 are located within an extended haplotype covering CH25H and LIPA (encoding lipase A, also known as cholesterol ester hydrolase). LIPA was not found to be differentially expressed in our analysis. Because the reported linkage peak on 10q may result from the combined effect of multiple susceptibility genes, we assessed the association between AD and 18 possibly relevant genes within a 20-cM-broad region on 10q23-24. Both SNPs and extended haplotypes were analyzed in 446 AD patients and 410 unrelated control subjects from Switzerland and the Mediterranean region (Greece and Italy). SNP CH25H*1 showed significant allelic association with AD (p = 0.0002, fi g. 3 a). Fine mapping of an 18-kb region around CH25H*1 and subsequent estimated haplotype analysis revealed strong LD between SNPs CH25H*1 and CH25H*2 in the Swiss population (p ! 0.001) and weak LD in the Mediterranean population (p = 0.02). Association mapping of two synonymous SNPs in CH25H , fi ve SNPs in the 5 region of the gene and three SNPs in the adjacent LIPA gene in the Swiss population revealed signifi cant allelic association of CH25H*1 , CH25H*2 , and CH25H*7 with AD ( fi g. The odds ratios and 95% confi dence intervals were 3.1 (2.1-4.5) for APOE4 carriers and 2.7 (1.5-4.8) for CH25H 4 carriers. In addition to CH25H , two additional haplotypes containing CH25H*1 showed significant, yet less pronounced association with AD ( fi g. 3 b). Seventeen SNPs within the examined region on 10q failed to show signifi cant allelic association with AD in the study populations.
SNP CH25H*2 is located within the core sequence (CTTG) of the functional binding site for the steroidogenic factor 1 (SF-1) [25, 26] , which is involved in the transcriptional regulation of steroid hydroxylases [27] and lipoprotein receptors [28] . Because allele A of CH25H*2 eliminates the SF-1 binding site, which results in impaired activity of SF-1-dependent regulatory regions [25] , and because CH25H is a potent regulator of cholesterol synthesis [4] , we examined whether the CH25H*2 -containing haplotype CH25H is associated with the levels of metabolic precursors of cholesterol. We found that the concentration of the cholesterol precursor lathosterol in CSF of CH25H 4 carriers was signifi cantly higher than in non-carriers ( fi g. 4 a).
To investigate whether CH25H exerts effects relevant to the pathophysiology of AD, we examined whether CH25H haplotypes differentially affected A ␤ plaque pathology. Brain samples from the medial temporal lobes of AD patients are ill suited for the study of genetic effects on amyloid load because they invariantly show highest levels of A ␤ plaque pathology. Therefore, we prevented such ceiling effects and examined the brains of 71 elderly non-demented subjects (age at death 6 50 years). We observed that both CH25H 4 and CH25H 3 were associated with high scores of brain A ␤ deposition, whereas no A ␤ deposits were present in CH25H 2 carriers (p = 0.002, table 2 ). In contrast, Braak's NFT staging [18] was similar among haplotype groups (p = 0.7). The CH25H -related differences in brain A ␤ deposition were paralleled by low CSF levels of A ␤ 42 in CH25H 4 carriers, intermediate levels in CH25H 3 carriers, and high levels in CH25H 2 carriers ( fi g. 4 b, c).
Second-Stage Analysis
The signifi cant association of SNP CH25H*1 with the risk for AD prompted us to validate this fi nding in ethnically independent case-control series from Russia (n = 164) and France (n = 1,216). We also genotyped a large sample of siblings who were part of the NIMH Human Genetics Initiative and the NCRAD (grant No. U24 AG21886) and applied family-based and case-control analytical methods.
Consistent with the fi ndings in the Swiss and Mediterranean populations, the T allele of CH25H*1 was significantly overrepresented in Russian AD patients as compared to control subjects (p = 0.031, table 3 ). This was not the case in the French sample (p = 0.3). Family-based analysis (using both the FBAT and the SDT algorithms) in the NIMH sample also failed to yield signifi cant results (p 1 0.1). Discrepancies between family-based and casecontrol approaches are common and may be related to the differential proportions of positive family history between samples [29] . Therefore, we selected from the sibpair sample a group of AD patients and unrelated control subjects to compare the family-based and case-control results in the same population. We selected the controls (n = 147) from sibships with at least one control subject. Where two or more control subjects were present, the oldest one was chosen. Unrelated AD patients (n = 211) were selected from the remaining sibships. Where possible, autopsy-verifi ed cases and controls were selected. Association analysis in that sample confi rmed the signifi cant results obtained in the Swiss, Mediterranean and Russian populations: the T allele of CH25H*1 was signifi cantly overrepresented in the US AD patients as compared to the control subjects (p = 0.015, table 3 ). Importantly, the genotype frequencies were nearly identical across populations. In addition, a compound analysis in the pooled case-control sample (1,282 AD patients and 1,312 control subjects) revealed a signifi cant effect of the CH25H*1 SNP on AD risk (p = 0.006).
Discussion
Since the fi rst report of genetic linkage of sporadic AD to chromosome 10q [6] , subsequent studies narrowed down the genetic region of interest [5, 30, 31] . By combining the information of genome scans with a novel candidate gene approach that is based upon specifi c information on gene expression levels in the brain, we found evidence that CH25H is expressed differentially in brains of patients with AD, and that genetic variants in the vicinity of this gene are associated with the risk for sporadic AD. We obtained signifi cant associations in four ethnically independent populations, whereas no signifi cant association was observed in a sample of French patients and control subjects. Analysis in the pooled sample of 1,282 AD patients and 1,312 control subjects confi rmed the signifi cant association of CH25H*1 with AD. It is therefore unlikely that the fi ndings reported here are due to random effects or multiple testing. They rather underscore the importance of ethnicity as an important confounding factor in genetic association analyses.
In addition to the genetic fi ndings in the case-control populations, we found evidence that CH25H is related to the pathophysiology of AD, because the risk haplotype CH25H 4 was associated with high brain A ␤ load and low levels of soluble A ␤ 42 in the CSF. The association of CH25H 4 with high A ␤ load in the medial temporal lobe suggests that this genetic variant enhances pathologic amyloidogenesis in vulnerable areas of the human brain. At the same time, CH25H 4 was found to be related to low levels of soluble A ␤ 42 in the CSF. A ␤ is secreted as a soluble protein to the extracellular space, including CSF, as part of the normal constitutive metabolism of amyloid precursor protein [32] . Since the CSF is in direct contact with the extracellular space of the brain, biochemical changes in the brain may be refl ected in the CSF. However, the relationship between brain and CSF A ␤ is only poorly understood. Nevertheless, a decrease in CSF A ␤ 42 in AD might refl ect the deposition of the protein in senile plaques with low levels of soluble peptide remaining to diffuse to the CSF [33] . Indeed, low levels of CSF A ␤ 42 are robustly observed in AD, even in the very early stages [34] . Alternatively, the reduction in A ␤ 42 levels in the CSF of patients with AD may be secondary to a disturbance in the metabolism of amyloid precursor protein and A ␤ in already dysfunctional neurons. Either way, our results show an aggravation of this AD-related phenotype (i.e. low A ␤ 42 levels in the CSF) in carriers of the CH25H 4 haplotype and, thereby, are in favor of the hypothesized relationship between CH25H and amyloid metabolism.
In addition, carriers of CH25H 4 had increased CSF levels of the cholesterol precursor lathosterol, supporting possible physiological differences of the haplotypes in the transcriptional regulation of CH25H .
We conclude that CH25H is genetically associated with the risk for sporadic AD, with the severity of A ␤ deposition in the brain and with the levels of soluble A ␤ 42 in the CSF. By modulating the fl uidity and structural integrity of the cell membrane, cholesterol infl uences the membrane-bound proteolytic processing of amyloid precursor protein. We therefore hypothesize that the association of CH25H with AD is linked to the effects of CH25H on cellular cholesterol biosynthesis. In support of this hypothesis, the examined CH25H haplotype in the 5 fl anking region of the gene was related to the CSF levels of metabolic precursors of cholesterol. CH25H is located within an AD-linked chromosomal region on 10q. The available genetic data suggest the existence of more than one susceptibility gene in this region, possibly proximal to CH25H . Further studies are needed for the identifi cation of these genes, which in sum may contribute to a genetic risk profi le for sporadic late-onset AD.
